PT2356090T - Crystalline forms of fingolimod hcl - Google Patents

Crystalline forms of fingolimod hcl

Info

Publication number
PT2356090T
PT2356090T PT97483507T PT09748350T PT2356090T PT 2356090 T PT2356090 T PT 2356090T PT 97483507 T PT97483507 T PT 97483507T PT 09748350 T PT09748350 T PT 09748350T PT 2356090 T PT2356090 T PT 2356090T
Authority
PT
Portugal
Prior art keywords
crystalline forms
fingolimod hcl
fingolimod
hcl
crystalline
Prior art date
Application number
PT97483507T
Other languages
Portuguese (pt)
Inventor
Mutz Michael
Jordine Guido
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08168865 priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2356090T publication Critical patent/PT2356090T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
PT97483507T 2008-11-11 2009-11-10 Crystalline forms of fingolimod hcl PT2356090T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11

Publications (1)

Publication Number Publication Date
PT2356090T true PT2356090T (en) 2017-10-16

Family

ID=40521487

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97483507T PT2356090T (en) 2008-11-11 2009-11-10 Crystalline forms of fingolimod hcl

Country Status (14)

Country Link
US (2) US8530522B2 (en)
EP (1) EP2356090B1 (en)
JP (4) JP2012508216A (en)
KR (2) KR20130109254A (en)
CN (3) CN104788325A (en)
AU (1) AU2009315736B2 (en)
BR (1) BRPI0921826A2 (en)
CA (1) CA2743232C (en)
ES (1) ES2643161T3 (en)
MX (1) MX2011004962A (en)
PL (1) PL2356090T3 (en)
PT (1) PT2356090T (en)
RU (2) RU2015111229A3 (en)
WO (1) WO2010055028A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041358A1 (en) 2010-10-01 2012-04-05 Synthon B.V. Process for making fingolimod hydrochloride crystals
CA2815634A1 (en) 2010-10-28 2012-05-03 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2646409A4 (en) * 2010-11-25 2015-12-16 Shilpa Medicare Ltd Fingolimod polymorphs and their processes
EP2658840B1 (en) 2010-12-28 2019-07-03 Synthon BV Process for making fingolimod hydrochloride crystals
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
WO2012146980A2 (en) 2011-04-29 2012-11-01 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
CA2887385C (en) 2011-05-26 2017-01-10 Glycoregimmune, Inc. Carrying On Business As Gri Bio, Inc. Hydroxy-substituted amino and ammonium derivatives and their medical use
DK2809318T3 (en) * 2011-05-26 2019-07-22 Gri Bio Inc Ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
ES2727038T3 (en) 2011-05-26 2019-10-11 Gri Bio Inc Oxygenated sulfonic acid derivatives containing amino or ammonium and their medical use
EA028950B1 (en) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Process for preparing pharmaceutical compositions comprising fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (en) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 Method for preparing fingolimod mucate and crystals thereof and application of fingolimod mucate and crystals thereof
EP2945927A4 (en) * 2013-01-17 2017-01-18 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
KR20150126876A (en) 2013-03-05 2015-11-13 바이오콘 리미티드 A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (en) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Crystalline h-modification of 2-amino-2-(2-(4-octylphenyl) ethyl)propane-1,3-diole hydrochloride, method for its production and pharmaceutical composition based thereon
CN106667981B (en) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 Fingolimod hydrochloride is preparing the application in medicine physical property liver injury medicament
CN106860440A (en) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 Application of the fingolimod hydrochloride in systemic lupus erythematosus encephalopathic medicine is prepared

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (en) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-amino-1,3-propanediol compound and immunosuppressant.
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP4079505B2 (en) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 Novel process for the preparation of 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol
AU1161400A (en) * 1998-11-11 2000-05-29 Abel, Stephan Production of 2-amino-2-(2-(4-C2-20-alkyl-phenyl)ethyl)propane-1 ,3-diols
PT1031347E (en) * 1999-01-27 2002-09-30 Idea Ag Transnational transmission / immunization with most adaptable vehicles
NZ514095A (en) * 1999-02-10 2001-09-28 Welfide Corp Amide compounds and medicinal use thereof
CN1144779C (en) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 Process for preparing alkylphenylethyl aminopropanediol and inter mediate obtained therein
US20030003099A1 (en) * 2001-06-08 2003-01-02 Philip Lake Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
ES2316758T3 (en) * 2002-05-16 2009-04-16 Novartis Ag Use of edg receiver binders in cancer.
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
NZ586280A (en) 2003-04-08 2011-12-22 Novartis Ag Oral pharmaceutical composition comprising FTY720 and mannitol
CN1212308C (en) * 2003-07-24 2005-07-27 漆又毛 Process for preparing 2-amino-2-(2-(4-otylphenyl)ethyl)-1,3-propylene glycol hydrochloride
CN1241903C (en) * 2003-10-14 2006-02-15 马启明 Method for preparing 2-para octylphenyl ehtyl-2-amino propanediol
TWI418350B (en) * 2005-06-24 2013-12-11 Sankyo Co Use of pharmaceutical compositions comprising ppar modulator
BRPI0616640A2 (en) * 2005-09-30 2011-06-28 Novartis Ag Combination of organic compounds
AU2006307939B2 (en) * 2005-10-26 2012-03-29 Merck Serono Sa Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN1310869C (en) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method
CN100548968C (en) * 2006-03-01 2009-10-14 徐州师范大学 Method for preparing 2-P-octyl-phenenl-2-amino-propanediol hydrochloride
ES2414205T3 (en) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
JP2010504364A (en) * 2006-09-26 2010-02-12 ノバルティス アーゲー Pharmaceutical composition comprising S1P modulator
CA2728514A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating multiple sclerosis
WO2012041358A1 (en) 2010-10-01 2012-04-05 Synthon B.V. Process for making fingolimod hydrochloride crystals

Also Published As

Publication number Publication date
ES2643161T3 (en) 2017-11-21
AU2009315736B2 (en) 2013-08-29
WO2010055028A2 (en) 2010-05-20
US20140051766A1 (en) 2014-02-20
CN107233336A (en) 2017-10-10
JP2012508216A (en) 2012-04-05
AU2009315736A1 (en) 2010-05-20
US20110229501A1 (en) 2011-09-22
RU2011123371A (en) 2012-12-20
US8530522B2 (en) 2013-09-10
RU2015111229A (en) 2015-11-20
BRPI0921826A2 (en) 2016-01-12
JP2014139179A (en) 2014-07-31
KR101393994B1 (en) 2014-05-14
RU2549899C2 (en) 2015-05-10
PL2356090T3 (en) 2017-12-29
WO2010055028A3 (en) 2010-07-08
CA2743232A1 (en) 2010-05-20
MX2011004962A (en) 2011-05-30
KR20110069156A (en) 2011-06-22
JP2018035160A (en) 2018-03-08
JP2016028056A (en) 2016-02-25
CA2743232C (en) 2015-12-29
KR20130109254A (en) 2013-10-07
CN104788325A (en) 2015-07-22
EP2356090B1 (en) 2017-07-05
RU2015111229A3 (en) 2018-11-08
EP2356090A2 (en) 2011-08-17
CN102209705A (en) 2011-10-05

Similar Documents

Publication Publication Date Title
EP2397459A4 (en) Method for producing phenylacetamide compound
GB0919423D0 (en) Novel compounds
GB0919434D0 (en) Novel compounds
GB0919426D0 (en) Novel compounds
GB0919431D0 (en) Novel compounds
EP2496846A4 (en) Flexible spring fastener
GB0909984D0 (en) Fastener
PL2398483T3 (en) Oxyntomodulin analogs
IL218674D0 (en) Novel compounds
IL213992D0 (en) Pro-neurogenic compounds
IL200382D0 (en) Methods of forming activated carbons
HK1177120A1 (en) Toothbrush
PL2586782T3 (en) Crystalline salts of sitagliptin
GB0905955D0 (en) Novel compounds
ZA201202106B (en) Substituted amide compound
IL215147D0 (en) Compounds
EP2277858A4 (en) Amide compound
EP2393493A4 (en) Compounds
GB0907425D0 (en) Compounds
EP2518338A4 (en) Clip
DK2262793T3 (en) Crystalline forms of nilotinib-hci
HK1144239A1 (en) Toothbrush
HRP20130026T1 (en) A crystalline form of posaconazole
IL243293D0 (en) Crystals
IL219248D0 (en) Compounds